- Biophytis and LynxKite launch new modalities beyond MASSIVE: an AI-based medicine discovery of next generation longevity therapies
- This partnership will generate revenue through:
- A longevity informatics platform, including unique datasets and accelerated calculation methods relevant to longevity research
- New generation drug candidates for sarcopenia
- Next-generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ — Lynxkite extends its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis”), starting with the MASSIVE project (Synthetic innovation of MAS receptors and virtual engineering for the treatment of sarcopenia) and plans to extend the platform to other modalities. This strategic initiative, also supported by Singapore’s Enterprise Singapore, aligns with the priority target areas of Singapore’s Research, Innovation and Enterprise (RIE) 2030 plan.
LynxKite Technologies, a leader in advanced analytics and artificial intelligence known for its flagship open source platform LynxKite, will integrate AI computational methods relevant to longevity research into its IT orchestration platform. With over a decade of experience, the LynxKite founding team has helped over 100 global companies, including major players such as Roche, AstraZeneca and Hummingbird Biosciences, analyze complex data using graph-based and generative AI approaches.
The first MASSIVE project aims to identify and develop Mas receptor (MasR) activating drug candidates targeting sarcopenia, a degenerative muscle disease associated with aging that affects millions of elderly people worldwide. Biophytis brings its deep expertise in age-related diseases, its preclinical experience in MasR-related indications and its expertise in Mas receptor pharmacology. LynxKite brings cutting-edge AI, chemoinformatics and software engineering technologies, combined with scalable GPU computing on the latest generation of NVIDIA toolkits and neoclouds such as Nebius. Together, the partners strengthen Biophytis’ strategic drug discovery program, aligned with its longevity-focused strategy and positioning.
The main objectives of the project include:
- Mas receptor modeling for structure-based drug design using AI and protein prediction tools.
- Design and prioritize synthetic drug candidates using AI-guided molecule generation and predictive filtering.
- Synthesize and test promising MasR activators to evaluate biological activity, safety and pharmacokinetics.
- Selection and protection of the lead candidate through patent filings in preparation for preclinical development.
- Develop and validate AI software through feedback loops in vitro And alive validation of candidates.
“The launch of MASSIVE marks a milestone in our longevity strategy, combining our clinical expertise with LynxKite’s innovative AI to accelerate the discovery of transformative therapies for sarcopenia. » said Stanislas Veillet, CEO of Biophytis.
Gyorgy Lajtai, CEO of LynxKite, added: “We are proud to collaborate with Biophytis on pioneering computing longevity through our LynxKite platform, which demonstrates how LynxKite can revolutionize discovery by designing, integrating and orchestrating relevant computing tools in various modalities.
About LynxKite
LynxKite Technologies Pte Ltd, headquartered in Singapore with offices in the United States and Switzerland. The LynxKite platform combines graph analytics and biological language models, while automatically managing, optimizing, and scaling GPU resources to efficiently run complex pipelines such as NVIDIA NIM microservices. Building on more than a decade of experience in graphs and enterprise AI, LynxKite collaborates with research institutions, technology partners, and industry leaders to accelerate scientific discovery and advanced analytics. For more information, please visit https://lynxkite.com.
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscle diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, and has subsidiaries in Cambridge, Massachusetts, the United States and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS – FR001400OLP5) and its ADSs (American Depositary Shares) are listed on the OTC market (BPTSY – US 09076G401). For more information, visit www.biophytis.com.
About I won’t do it
Nebius, the AI cloud company, is building the full-stack platform for developers and businesses to support the future of their AI, from training data and models to deployment in production. Built on deep in-house technology expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises creating AI products, agents and services around the world. Nebius is listed on Nasdaq (NASDAQ: NBIS) and is headquartered in Amsterdam. For more information, please visit www.nebius.com.
View original content to download multimedia:^ https://www.prnewswire.com/apac/news-releases/biophytis-lynxkite-alliance-expands-to-turbocharge-ai-driven-drug-discovery-for-next-generation-longevity-therapeutics-302713534.html
SOURCE Biophytis; LynxKite Technologies
